Viatris wins court decisions on sanofi appeals of lantus® patent invalidations

Pittsburgh, dec. 29, 2021 /prnewswire/ -- viatris inc. (nasdaq: vtrs) announced that it is pleased with decisions issued today which affirm the u.s. patent and trademark appeal board's prior rulings that found the challenged claims of sanofi's lantus® solostar® device patents, u.s. patent nos. 9,603,044, 8,992,486, 9,526,844, 9,604,008, and 8,679,069, unpatentable.

VTRS Ratings Summary

VTRS Quant Ranking